Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.